PharmAla Biotech files a patent on 6 new MDMA molecules

PharmaAla biotechnologies (CSE: MDMA) has now made more progress in its quest to become an industry leader and promote MDMA therapy.

On Monday, the Canadian biotech company announced that it had filed a patent cooperation treaty (PCT) application for six new chemical entities (NCEs).

These NCEs include a series of new MDMA compositions intended to alleviate the side effects associated with the regular form of the drug while maintaining the same level of efficacy for the treatment of mental health disorders.

Read more: PharmAla Biotech becomes the first public company producing GMP MDMA

Read more: PharmAla Biotech launches MDMA supplier agreement with InterVivo

PharmAla is a biotechnology company with a professional team of scientists, regulatory experts and biomanufacturing specialists. The organization is focused on the development of clinical grade MDMA and NCE.

The PCT application now filed by the company is an international application applicable in 153 countries around the world and administered by the World Intellectual Property Organization (WIPO), according to the Government of Canada.

The company claims that as a result of preclinical animal studies at the University of Arkansas School of Medical Sciences (UAMS), its “ALA” series of MDMA analogs showed a pharmacology of improved security compared to standard MDMA. Significantly reduced levels of neurotoxicity, hyperthermia and cardiotoxicity as well as a maintained level of therapeutic value are hallmarks of analogs, according to PharmAla.

The ALA series is made up of three unique NCEs, but the company currently plans to advance only one of these molecules to investigational new drug (IND) status.

“MDMA is a fascinating molecule with a troubled history. The therapeutic potential of this compound has been evident from its inception, but its potential for abuse and adverse effects is equally remarkable,” said Dr. Guillaume FantegrossiPrincipal Investigator for PharmAla Biotech at UAMS.

“The work done at PharmAla to create formulations that retain therapeutic efficacy while minimizing harm is extremely important to the future of MDMA as a medicinal agent, and the drug development strategy that their work exemplifies at through this patent is a model for the field of ‘psychedelics'”. medicine’ as a whole,” added Dr. Fantegrossi.

The patent filing by PharmAla will further contain the company’s series of ABA molecules, which the biotechnology team says are composed of an analog of MDMA that is not currently classified as a controlled substance in Canada. The company also says it will sue one of its three ABA NCEs in an “ex-US jurisdiction” where PharmAla will benefit from its non-controlled substance status allowing for faster and more cost-effective research.

“Addressing the toxicology of generic MDMA using new compositions and drug molecules has been the primary focus of our work. This patent application reinforces our position in the industry as pioneers in the development of MDMA. Given that we are the only public company to have manufactured GMP MDMA, this is entirely appropriate,” said Dr. Harpreet Kaurvice president of research at PharmAla Biotech.

“There is a serious unmet need for patients with mental health issues. Psychedelics continue to demonstrate their benefits through multiple clinical trials. However, as a “regulatory first” company, we know that regulators and the general public demand exemplary safety from pharmaceutical products such as MDMA; This patent represents our first step in reaching that high bar,” added Dr. Kaur.

Follow Mugglehead on Twitter

Like Mugglehead on Facebook

About Cecil Cobb

Check Also

New organizational US dating app provides security features to protect 50 million app users

In the United States, there are currently over 50 million dating app users. That’s a …